{"nctId":"NCT00063635","briefTitle":"Treatment of Nonalcoholic Fatty Liver Disease in Children (TONIC)","startDateStruct":{"date":"2005-09"},"conditions":["Fatty Liver"],"count":173,"armGroups":[{"label":"1","type":"ACTIVE_COMPARATOR","interventionNames":["Drug: Metformin"]},{"label":"2","type":"ACTIVE_COMPARATOR","interventionNames":["Dietary Supplement: Vitamin E"]},{"label":"3","type":"PLACEBO_COMPARATOR","interventionNames":["Drug: Matching placebo"]}],"interventions":[{"name":"Metformin","otherNames":[]},{"name":"Vitamin E","otherNames":["Nature Made"]},{"name":"Matching placebo","otherNames":[]}],"eligibilityModule":{"eligibilityCriteria":"* Age 8-17 years at first screening visit\n* Histologic evidence of Nonalcoholic Fatty Liver Disease (NAFLD) - biopsy cannot be older than 6 months as of randomization\n* ALT level \\>60 U/L at time of screening and on one previous occasion determined at least one month but no greater than 6 months prior to screening ALT\n* Consent","healthyVolunteers":false,"sex":"ALL","minimumAge":"8 Years","maximumAge":"17 Years","stdAges":["CHILD"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Number of Participants With Sustained Reduction in Alanine Aminotransferase (ALT) to Either 50% of Baseline Value or < 40 IU/L","description":"The primary outcome was sustained reduction in ALT level, defined as 50% or less of the baseline level or 40 IU/L or less at each visit from 48 to 96 weeks of treatment.","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"9","spread":null},{"groupId":"OG001","value":"15","spread":null},{"groupId":"OG002","value":"10","spread":null}]}]}]},{"type":"SECONDARY","title":"Change in Serum Aspartate Aminotransferase (AST)","description":null,"paramType":"MEAN","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-21.5","spread":null},{"groupId":"OG001","value":"-22.8","spread":null},{"groupId":"OG002","value":"-20.4","spread":null}]}]}]},{"type":"SECONDARY","title":"Change in Nonalcoholic Fatty Liver Disease (NAFLD) Score (Histologic Feature Scores Determined by Standardized Scoring of Liver Biopsies) From Baseline at 96 Weeks of Treatment","description":"Histological activity was assessed using the NAFLD activity score on a scale of 0 to 8, with higher scores indicating more severe disease; the components of this measure include steatosis (0-3), lobular inflammation (0-3), and hepatocellular ballooning (0-2).","paramType":"MEAN","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-1.1","spread":null},{"groupId":"OG001","value":"-1.8","spread":null},{"groupId":"OG002","value":"-0.7","spread":null}]}]}]},{"type":"SECONDARY","title":"Number of Participants With Improvement in Liver Fibrosis Score","description":"Fibrosis is assessed on a scale of 0 to 4 with higher scores indicating more severe fibrosis. This secondary outcome measure is the number of participants that experienced a decrease in fibrosis score at 96 weeks compared to baseline, which indicates improvement in fibrosis.","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"22","spread":null},{"groupId":"OG001","value":"18","spread":null},{"groupId":"OG002","value":"19","spread":null}]}]}]},{"type":"SECONDARY","title":"Number of Participants With Improvement in Steatosis Score","description":"Steatosis is assessed on a scale of 0 to 3 with higher scores indicating more severe steatosis. This secondary outcome measure is the number of participants that experienced a decrease in steatosis score at 96 weeks compared to baseline, which indicates improvement in steatosis.","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"26","spread":null},{"groupId":"OG001","value":"27","spread":null},{"groupId":"OG002","value":"19","spread":null}]}]}]},{"type":"SECONDARY","title":"Number of Participants With Improvement in Lobular Inflammation Score","description":"Lobular inflammation is assessed on a scale of 0 to 3 with higher scores indicating more severe lobular inflammation. This secondary outcome measure is the number of participants that experienced a decrease in lobular inflammation score at 96 weeks compared to baseline, which indicates improvement in lobular inflammation.","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"23","spread":null},{"groupId":"OG001","value":"22","spread":null},{"groupId":"OG002","value":"20","spread":null}]}]}]},{"type":"SECONDARY","title":"Number of Participants With Improvement in Ballooning Degradation Score","description":"Ballooning is assessed on a scale of 0 to 2 with higher scores indicating more severe ballooning. This secondary outcome measure is the number of participants that experienced a decrease in ballooning score at 96 weeks compared to baseline, which indicates improvement in ballooning.","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"22","spread":null},{"groupId":"OG001","value":"22","spread":null},{"groupId":"OG002","value":"10","spread":null}]}]}]},{"type":"SECONDARY","title":"Change in Body Mass Index","description":null,"paramType":"MEAN","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1.3","spread":null},{"groupId":"OG001","value":"2.1","spread":null},{"groupId":"OG002","value":"1.9","spread":null}]}]}]},{"type":"SECONDARY","title":"Change in Serum Vitamin E Levels","description":"Change in alpha-Tocopherol","paramType":"MEAN","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.5","spread":null},{"groupId":"OG001","value":"9.4","spread":null},{"groupId":"OG002","value":"-0.9","spread":null}]}]}]},{"type":"SECONDARY","title":"Change in Quality of Life (QOL) Scores- Physical Health","description":"Change in self-reported QOL physical health Pediatric Quality of Life Inventory (version 4.0) scores were recorded to range from 0 to 100 with increasing scores indicating better quality of life.","paramType":"MEAN","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"5.4","spread":null},{"groupId":"OG001","value":"7.6","spread":null},{"groupId":"OG002","value":"5.4","spread":null}]}]}]},{"type":"SECONDARY","title":"Change in QOL- Psychosocial Health","description":"Change in self-reported QOL physical health Pediatric Quality of Life Inventory (version 4.0) scores were recorded to range from 0 to 100 with increasing scores indicating better quality of life.","paramType":"MEAN","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"4.0","spread":null},{"groupId":"OG001","value":"6.0","spread":null},{"groupId":"OG002","value":"5.6","spread":null}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":7,"n":57},"commonTop":["Unspecified- Mild","Unspecified- Moderate"]}}}